INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 453m ago
HOUSE PTR53m ago
SEC 13F53m ago
ROBINHOOD CHAIN53m ago
SEC FORM 4/Grant or awardVerified data

Lee Han Myung reported IPSC

Director · Century Therapeutics, Inc. · Century Therapeutics, Inc. — Stock Option (right to buy)

Side
A
Value
—
Shares
74.0K
Price
—
Executed
Jun 11, 2026
Disclosed
Jun 12, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jun 11 executedJun 12, 2026 disclosed

IPSC · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IPSC

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    14
    CD
    Carr DouglasSVP Finance & Operations
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$404
    266 sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    19
    CD
    Carr DouglasSVP Finance & Operations
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$3,200
    1,658 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    5
    PB
    Pfeiffenberger BrentDirector, President and CEO
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$27K
    13.8K sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    22
    RG
    Russotti GregorySee Remarks
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$4,993
    2,587 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    19
    CD
    Carr DouglasSVP Finance & Operations
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$521
    254 sh
    		Sep 8, 2026Sep 9, 2026
    traded Sep 8, 2026
    		+1dSEC FORM 4

    Evidence

    22
    RG
    Russotti GregorySee Remarks
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$1,095
    534 sh
    		Sep 8, 2026Sep 9, 2026
    traded Sep 8, 2026
    		+1dSEC FORM 4

    Evidence

    11
    PB
    Pfeiffenberger BrentDirector, President and CEO
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$977
    463 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    8
    PB
    Pfeiffenberger BrentDirector, President and CEO
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$60K
    31.2K sh
    		Aug 14, 2026Aug 18, 2026
    traded Aug 14, 2026
    		+4dSEC FORM 4

    Evidence

    5
    PB
    Pfeiffenberger BrentDirector, President and CEO
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$31K
    13.8K sh
    		Jun 11, 2026Jun 15, 2026
    traded Jun 11, 2026
    		+4dSEC FORM 4

    Evidence

    22
    RG
    Russotti GregorySee Remarks
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$5,767
    2,584 sh
    		Jun 12, 2026Jun 15, 2026
    traded Jun 12, 2026
    		+3dSEC FORM 4

    Evidence

    22
    CD
    Carr DouglasSVP Finance & Operations
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$3,692
    1,654 sh
    		Jun 12, 2026Jun 15, 2026
    traded Jun 12, 2026
    		+3dSEC FORM 4

    Evidence

    5
    CC
    Cowan ChadChief Scientific Officer
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$802
    358 sh
    		Jun 11, 2026Jun 15, 2026
    traded Jun 11, 2026
    		+4dSEC FORM 4

    Evidence

    9
    MP
    Murphy Martin PatrickDirector
    IPSCCentury Therapeutics, Inc.
    Grant or award
    		A—
    74.0K sh
    		Jun 11, 2026Jun 12, 2026
    traded Jun 11, 2026
    		+1dSEC FORM 4

    Evidence

    5
    PB
    Pfeiffenberger BrentDirector, President and CEO
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$986
    463 sh
    		Jun 5, 2026Jun 9, 2026
    traded Jun 5, 2026
    		+4dSEC FORM 4

    Evidence

    22
    RG
    Russotti GregorySee Remarks
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$1,106
    524 sh
    		Jun 8, 2026Jun 9, 2026
    traded Jun 8, 2026
    		+1dSEC FORM 4

    Evidence

    22
    CD
    Carr DouglasSVP Finance & Operations
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$526
    249 sh
    		Jun 8, 2026Jun 9, 2026
    traded Jun 8, 2026
    		+1dSEC FORM 4

    Evidence

    8
    PB
    Pfeiffenberger BrentDirector, President and CEO
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$73K
    31.2K sh
    		May 15, 2026May 19, 2026
    traded May 15, 2026
    		+4dSEC FORM 4

    Evidence

    17
    CD
    Carr DouglasSVP Finance & Operations
    IPSCCentury Therapeutics, Inc.
    Open-market sale
    		SELL$618
    264 sh
    		May 4, 2026May 6, 2026
    traded May 4, 2026
    		+2dSEC FORM 4

    Evidence

    24
    MP
    Murphy Martin PatrickDirector
    IPSCCentury Therapeutics, Inc.
    Grant or award
    		A—
    88.0K sh
    		Dec 9, 2025Apr 10, 2026
    traded Dec 9, 2025
    		+122dSEC FORM 4

    Evidence

    5
    CC
    Cowan ChadChief Scientific Officer
    IPSCCentury Therapeutics, Inc.
    Tax withholding
    		F$2,989
    1,365 sh
    		Apr 1, 2026Apr 3, 2026
    traded Apr 1, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002100154-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 11, 2026
    Published
    Jun 12, 2026
    Ingested by INSIDER
    Nov 5, 03:53 UTC
    Last re-read
    Nov 5, 03:53 UTC

    Extracted facts

    Filer
    Lee Han Myung
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Century Therapeutics, Inc. — Stock Option (right to buy)
    Ticker
    IPSC
    Shares
    74.0K
    Price per share
    $0
    Execution date (reported)
    Jun 11, 2026
    Owned after transaction
    74.0K shares
    Days from execution to publication
    1

    What this establishes

    Lee Han Myung filed this Form 4 reporting a grant or award of IPSC on Jun 11, 2026. It became public on Jun 12, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Lee Han Myungcik:0002100154
    Issuer
    Century Therapeutics, Inc.cik:0001850119

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.